1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

BioNotebook: PhaseBio closes $40m Series C round led by AstraZeneca, plus five other VC financings

 
• By Mandy Jackson

AstraZeneca led a $40m Series C venture capital round that will fund PhaseBio's Phase IIa clinical trials for drug candidates to treat diabetes and heart failure – two key areas of interest for the UK-based big pharma company.

AstraZeneca led a $40m Series C venture capital round that will fund PhaseBio's Phase IIa clinical trials for drug candidates to treat diabetes and heart failure – two key areas of interest for the UK-based big pharma company.

PhaseBio's recently appointed CEO Jonathan Mow, who previously was chief business officer, said AstraZeneca has "an option to option" the company's novel, once-weekly insulin (scripintelligence.com, 5 March 2015). PhaseBio...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

More from Therapy Areas

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By Kevin Grogan

Buy boosts the French major's immunology pipeline.

ASCO: AstraZeneca Changes Management Of Breast Cancer Resistance With SERENA-6

 
• By Mary Jo Laffler

AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.